151 related articles for article (PubMed ID: 36674612)
1. Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the
Czarny J; Andrzejewska M; Zając-Spychała O; Latos-Grażyńska E; Pastorczak A; Wypyszczak K; Szczawińska-Popłonyk A; Niewiadomska-Wojnałowicz I; Wziątek A; Marciniak-Stępak P; Dopierała M; Małdyk J; Jończyk-Potoczna K; Derwich K
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674612
[TBL] [Abstract][Full Text] [Related]
2. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
3. Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.
Sato D; Moriya K; Nakano T; Miyagawa C; Katayama S; Niizuma H; Sasahara Y; Kure S
Int J Hematol; 2021 Dec; 114(6):735-741. PubMed ID: 34424493
[TBL] [Abstract][Full Text] [Related]
4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
5. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.
Huntington SF; Talbott MS; Greer JP; Morgan DS; Reddy N
Leuk Lymphoma; 2012 Aug; 53(8):1461-8. PubMed ID: 22260160
[TBL] [Abstract][Full Text] [Related]
6. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
7. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
9. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
10. The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency.
Harada K; Kimura K; Iwamuro M; Terasaka T; Hanayama Y; Kondo E; Hayashi E; Yoshino T; Otsuka F
Intern Med; 2017 Sep; 56(17):2261-2269. PubMed ID: 28794358
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.
Sandlund JT; Hudson MM; Kennedy W; Onciu M; Kastan MB
Pediatr Blood Cancer; 2014 Feb; 61(2):360-2. PubMed ID: 23900766
[TBL] [Abstract][Full Text] [Related]
12. Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.
Rossi G; Zecca M; Marchi A; de Stefano P; Sammarchi L; Locatelli F
Br J Haematol; 2003 Jan; 120(2):369-71. PubMed ID: 12542504
[No Abstract] [Full Text] [Related]
13. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
14. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
16. [Rupture of hepatic lesion of diffuse large B-cell lymphoma following immunochemotherapy].
Segawa R; Natazuka T
Rinsho Ketsueki; 2022; 63(3):211-216. PubMed ID: 35387935
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
18. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
19. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
20. Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report.
Tekinalp A; Kars TU; Dikici HZ; Yılmaz PD; Demircioğlu S; Çeneli Ö
J Oncol Pharm Pract; 2022 Mar; 28(2):449-452. PubMed ID: 34549658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]